Nimotuzumab 生物類似藥, EGFR 單克隆抗體-Nimotuzumab Biosimilar, EGFR Monoclonal Antibody代理/參數(shù)/廠家-二抗-艾美捷科技有限公司

PRODUCT CENTER

二抗

產(chǎn)品中心

當(dāng)前位置：首頁 > 產(chǎn)品中心 > 免疫學(xué)產(chǎn)品 > 二抗

購買方式: 90%產(chǎn)品中國(guó)有現(xiàn)貨庫存。銀行轉(zhuǎn)賬、電匯、支票、現(xiàn)金，在線支付寶及網(wǎng)銀支付，或直接與我們電話聯(lián)系400-6800-868

背景資料: Nimotuzumab Biosimilar uses the same protein sequences as the therapeutic antibody nimotuzumab.nnLike cetuximab, nimotuzumab is a humanized monoclonal antibody that binds to the epidermal growth factor receptor (EGFR), a signalling protein that normally controls cell division. In some cancers, this receptor is altered to cause uncontrolled cell division, a hallmark of cancer. These monoclonal antibodies block EGFR and stop the uncontrolled cell division.nnIt has a humanized human-mouse h-R3 heavy chain and a humanized human-mouse h-R3 κ-chain.nnNimotuzumab binds with optimal affinity and high specificity to the extracellular region of EGFR (epidermal growth factor receptor). This results in a blockade of ligand binding and receptor activation. Epidermal growth factor receptor (EGFR) is a key target in the development of cancer therapeutics. EGFR-targeting drugs have been shown to improve response when used with conventional treatments such as radiation therapy and chemotherapy.

保存建議: Store at 4°C 1 month, store at -20°C to -70°C 12 month. protected from prolonged exposure to light. Avoid freeze/thaw cycles.

其他: ProMab 生物技術(shù)公司通過整合生物信息學(xué)、分子生物學(xué)、蛋白質(zhì)表達(dá)、純化技術(shù)、基因克隆、微生物學(xué)和免疫學(xué)，利用新型高通量技術(shù)開發(fā)重組蛋白、抗體和工程細(xì)胞系并將其商業(yè)化。專注于免疫治療領(lǐng)域，特別是 CAR-T/NK 細(xì)胞技術(shù)。ProMab 還開發(fā)了一種新型的 mRNA 脂質(zhì)納米顆粒（mRNA-LNP）平臺(tái)，用于即用型試劑和定制研究服務(wù)，以推進(jìn)現(xiàn)有產(chǎn)品并擴(kuò)展到更多的研究領(lǐng)域。